Stay updated with the latest healthcare breakthroughs, including Bayer's finerenone expanding to type 1 diabetes-associated CKD.
News|Articles|March 3, 2026
6 Endocrinology Headlines You Missed in February 2026
Author(s)Ryan Livingston
Fact checked by: Chelsie Derman
Catch up with FDA decisions, key trial results, podcast updates, and more.
Advertisement
Advertisement
Related to this article
Diana Isaacs, PharmD, and Natalie Bellini, DNP, discuss the FDA's recent approval of Bayer's finerenone in concomitant CKD and T1D.
The approval, backed by FINE-ONE data showing a 28% UACR reduction at 6 months, is the first new CKD treatment for this group in 3 decades.
Diana Isaacs, PharmD, and Natalie Bellini, DNP, discuss Beta Bionics' new insulin patch pump, expected to be commercialized in Q1 2027.
Beta Bionics plans to launch Mint through the pharmacy channel in the first quarter of 2027.
Raj Chovatiya, MD, PhD, on zasocitinib results in the scalp, nails, palms and soles, speed of response and once-daily oral dosing in psoriasis.
Philadelphia-area PAH specialists discuss real-world patient mismatch with trial criteria, drug sequencing, and insurance access barriers.
FDA expands marstacimab approval to children and patients with inhibitors, backed by new BASIS trial data.
Advertisement
Advertisement